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Mitral regurgitation is one of the most commonly encountered valvular heart 
diseases in both the developing and the developed world. From various studies, it is 
known that chronic mitral regurgitation is associated with progressive left ven-
tricular dysfunction, and eventually death if left untreated. This disease has a long 
silent period before symptoms manifest. During this latent period, left ventricular 
function progressively deteriorates and results in poor outcomes for patients even 
if surgery is performed. A few studies have evaluated the role of medical therapy in 
patients with chronic mitral regurgitation. This chapter will provide an overview of 
the use of medical therapy in chronic mitral regurgitation.
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1. Introduction
In heart failure (HF), irrespective of aetiology, there is activation of the sym-
pathetic nervous system and the renin angiotensin system that initially serves as 
compensatory mechanism to maintain the falling cardiac output through retention 
of sodium and water, peripheral arterial vasoconstriction and increased cardiac 
contractility [1–3]. However, long term stimulation of these systems has a deleteri-
ous effect and results in cardiac remodelling and eventually irreversible HF in the 
absence of therapy [2, 4]. In HF due to chronic mitral regurgitation (MR) the afore-
mentioned mechanisms are activated and over time result in apoptosis, necrosis 
and myocyte slippage and left ventricular (LV) remodelling and dilatation from loss 
of interstitial collagen [3]. There are a number of studies that have evaluated the 
effects of drugs in degenerative MR. Most of these involved beta blockers or vasodi-
lators. The pathophysiologic basis for their use was to prevent the deleterious effect 
of sympathetic nervous system in MR, and medical therapy decreased afterload and 
LV wall stress, thus preventing deleterious remodelling [5].
In this review chapter a brief overview of aetiology and pathophysiology of MR 
will be provided, followed by the current perspective regarding the value of medical 
therapy in chronic MR will be discussed.
2. Definition and aetiology of mitral regurgitation
Chronic MR is a result of abnormality of the one or more of the components of 
the mitral valve apparatus [3, 6]. Mitral regurgitation can be a result of abnormality 
of mitral leaflet, chordae tendineae, papillary muscles and annulus.  
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It can be primary or secondary. Primary MR is confined to de novo abnormality 
of the mitral leaflet itself, whereas secondary MR is as a result of another disease 
process usually involving the LV, which results in a regurgitant mitral valve. Mitral 
regurgitation results in volume overload of the LV and culminates in left ventricular 
failure if left untreated.
There are numerous aetiologies of mitral regurgitation [6]. The common cause 
of MR in the developed world is due to degenerative disease and in the develop-
ing world MR is due to rheumatic heart disease (Figure 1). Other causes of MR 
include: infective endocarditis, trauma, drugs, congenital heart disease and 
annular calcification. Secondary mitral regurgitation is due to coronary artery 
disease, cardiomyopathies (dilated, hypertrophic cardiomyopathy) and right 
ventricular pacing.
3. Pathophysiology of chronic mitral regurgitation
The amount of blood regurgitating into the left atrium depends on the size of the  
regurgitant orifice and the pressure gradient between the LV and the left atrium [3]. 
The regurgitant orifice and the gradient between the LV and the left atrium are 
not static. The pressure gradient between the two chambers is dependent on the 
peripheral vascular resistance. The mitral annulus is a dynamic structure and thus 
any change in the preload, afterload, and contractility alters the size of the annulus 
due to alteration the LV size. Therefore, when the afterload, preload and contractil-
ity decrease, the size of the mitral annulus decreases and so does the regurgitant 
orifice. Vasodilators, inotropes and diuretics tend to decrease the size of the LV, thus 
decreasing the mitral annulus size and the area of regurgitant orifice and hence 
the regurgitant volume. Conversely, any condition that increases the size of the 
LV increases the mitral annulus size and size of the regurgitant orifice. Further, in 
addition to magnitude of the pressure gradient difference the duration of the gradi-
ent has an effect on volume of regurgitation [8].
Thus, in summary the regurgitant volume can be estimated by the following 
formulae [9]:
 Mitral Regurgitant Volume  =  Mitral Regurgitant Orifice Area × constant  
× Duration of pressure gradient × square root  (LV Pressure − Left Atrial Pressure) 
Figure 1. 
(A) Parasternal long-axis view depicting an eccentric anteriorly directed mitral regurgitation jet secondary 
to restricted posterior mitral leaflet motion. (B) Parasternal long-axis view depicting a contemporary patient 
with established rheumatic heart disease: thickened shortened chordae, restricted posterior mitral leaflet [7].
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By altering the LV and left atrial pressure gradient and the orifice size various 
drugs can decrease or increase the mitral regurgitant volume.
Chronic MR is characterised by a compensated, transitional and decompensated 
stage [3, 10]. The compensated stage is characterised by LV remodelling. During this 
stage there is preserved ejection fraction as a result of eccentric ventricular hyper-
trophy accompanied by an elevated end diastolic volume. There is laying down of 
sarcomere in series and a shift in pressure-volume curve to the right with a larger 
volume for any given pressure. The transition phase is characterised by a decline in 
LV ejection fraction, the regurgitant volume and an increase in the afterload and 
there is a decrease in myocardial contractility. If untreated, the patient progresses 
into the decompensated state characterised by neurohormonal activation. There is 
increased LV stiffness with an increase in end-diastolic and end-systolic volume, 
preload and afterload with a decline in ejection fraction and stroke volume.
The compensated and the transition phase present opportunity for surgical 
intervention before the decompensated phase sets in and irreversible myocardial 
damages ensue. Current valvular heart disease guidelines recommend use of 
medical therapy for heart failure in patients with mitral regurgitation [11]. Medical 
therapy in the form of vasodilators and diuretics can be used in patients who are 
in decompensated phase and are at a high risk for surgery, and in the compensated 
phase where there is no indication for surgery. In the compensated phase the use of 
vasodilators aims to decrease the afterload, as it may help delay time to surgery [12].
4. Medical therapy in chronic mitral regurgitation
In chronic MR the persistent volume overload results in activation of compensa-
tory mechanisms which include activation of sympathetic nervous system-renin 
angiotensin aldosterone system, the Frank-Starling mechanism and eccentric 
hypertrophy [3, 13]. Over the long-term, these compensatory mechanisms are 
deleterious and culminate in myocardial dysfunction and failure. These pathways 
have provided the rationale for benefit of medical therapy in MR. The following 
agents have been studied in chronic MR:
1. Vasodilators-angiotensin converting enzyme inhibitors (ACEI), angiotensin 
receptor blockers (ARB), hydralazine
2. Beta-blockers
3. Aldosterone receptor blockers
4. Combination anti-remodelling therapy
4.1 Vasodilators in chronic mitral regurgitation
Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor 
blockers (ARBs) reduce the severity of MR and hence HF symptoms by decreasing 
the afterload and potentially reversing the remodelling process. The decrease in pre-
dominantly peripheral vascular resistance results primarily in decrease in the size of 
the LV and thus size of the mitral annulus and that of the regurgitant orifice [14–16].
ACEIs have been used in the treatment of systolic HF with significant reductions 
in morbidity and mortality [17]. In the context of MR, benazepril was used in dogs 
with moderate to severe MR and showed improved survival [18]. Wisenbaugh et al. 
studied the effects of captopril in 32 patients with severe isolated MR over a 6-month 
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period, and found no difference in LV diameters or ejection fraction when compared 
to placebo [19]. In a trial on humans assessing a combined population of patients with 
moderate to severe aortic regurgitation and MR, a significant reduction in regurgitant 
fraction, LV end-systolic and end diastolic volumes and LV mass, was noted when 
quinapril was used [20]. One study looked at the use of lisinopril in patients with 
chronic moderate MR with preserved LV ejection fraction and without symptoms. 
Twenty-three patients were randomised to receive lisinopril or placebo for a period 
of 12 months. A decrease in regurgitant fraction was noted in the group on lisinopril 
compared to the placebo arm without a change in left atrial or LV size [21].
In a paediatric case-control study of patients with moderate to severe MR 
the effect of ACEI on LV size and function was small after a follow-up period of 
1 month to 1 year [22].
ARBs seem to produce a similar beneficial effect. In a, small study on the use 
of losartan for the treatment of MR, a modest but variable improvement in the 
severity of MR was noted. Specifically, the regurgitant volume and the effective 
regurgitant orifice decreased and the effect was durable for 1 month [15]. Another 
trial assessing moderate degenerative and rheumatic MR also found a beneficial 
effect with losartan over a 6-week period with regards to MR severity, LA size, and 
LV function [23].
Irbesartan was tested in an animal study. In this study irbesartan was adminis-
tered to animals with new onset MR for a duration of 3 months. It reduced periph-
eral vascular resistance in the study group compared to group that received no 
therapy. However, no effect on LV dimensions was noted [24].
Hydralazine and lisinopril in combination with isosorbide dinitrate have been 
studied in patients with HF complicated by secondary MR [25, 26]. Hydralazine was 
tested in a small study of 15 patients with HF and MR, it should a variable response 
with half the patients showing no or minimal improvement over a follow-up period 
of 13 months. A second study looked at the benefit of lisinopril and isosorbide 
dinitrate in patients with HF and MR. This study showed an overall improvement in 
symptoms, hospitalisations due to HF and in peak oxygen consumption. In terms of 
reduction in MR severity and LV size, the response was variable.
It is important to note the aetiology of MR when using drugs that venodilate. 
Venodilators tend to worsen MR in patients with a fixed orifice such as rheumatic 
heart disease. In these patients venodilation results in a decrease in pulmonary 
venous pressure and hence a decrease in left atrial pressure, which results in 
tendency of the blood to follow the path of least resistance, that is, from LV into 
the left atrium. A reduction in just the systemic vascular resistance as in patients 
with rheumatic MR and co-morbidity of hypertension results in decrease in MR 
severity [26].
4.2 Beta blockers in chronic mitral regurgitation
The adrenergic system becomes activated at an early stage in patients with mitral 
regurgitation [27]. It acts as a support mechanism to maintain the contractility and 
cardiac output in MR. However, catecholamines are deleterious overlong term. 
Increased catecholamines induce myocyte apoptosis [28]. Hence, beta blockers 
are beneficial by preventing cardiac myocyte death due to excessive sympathetic 
activity.
Beta-blockade has demonstrated efficacy in reducing mortality in patients with 
cardiac failure due to non-valvular causes [17]. In canine models with chronic experi-
mental MR chronic beta-blocker therapy improves LV function [13]. A pilot study 
involving patients with moderate to severe MR on beta-blocker therapy (metoprolol) 
was conducted over a 2-week period. Cardiac magnetic resonance imaging was used 
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to follow-up this cohort. No reduction in regurgitant volume was demonstrated, how-
ever, LV work was reduced by beta-blocker therapy [29]. A larger study was therefore 
proposed to assess the effect of beta-blockers on LV function and symptoms due to 
MR. A subsequent trial was published, involving patients with moderate to severe, 
degenerative MR on beta-blocker therapy, (metoprolol) over a 2-year follow-up. LV 
function was assessed using cardiac magnetic resonance imaging. Improvements 
were found in LV ejection fraction and LV early diastolic filling rate. No change in LV 
end-diastolic volume or LV end-systolic volume was noted [30].
4.3 Aldosterone receptor antagonist in chronic mitral regurgitation
Aldosterone play an important role in HF progression [31]. In HF there is a 
decline in cardiac output which results in the activation of neurohormonal system 
and the renin angiotensin aldosterone pathway. The increased level of aldosterone 
stimulates inflammation and cardiac fibrosis. This results in pathologic cardiac 
remodelling.
Spironolactone has been evaluated in the context of systolic HF resulting in 
favourable LV remodelling and a decline in morbidity and mortality through 
aldosterone antagonism [17, 32]. The mortality reduction in HF was attributed to a 
decrease in sudden death and progression of HF. No human trials with spironolac-
tone in MR have been noted in the literature. In dogs however, a study investigating 
spironolactone in moderate to severe MR resulted in a significant reduction (55%) 
in a composite end-point of cardiac-related death, euthanasia, or severe worsening 
of MR [33].
4.4 Combination anti-remodelling therapy in chronic mitral regurgitation
There is proven mortality and morbidity benefit of combination anti-remodelling 
therapy in systolic HF as a result of ischaemia and cardiomyopathies [17, 34, 35]. 
Guidelines on valvular heart disease recommend medical therapy for HF (EF < 50%) 
in chronic MR (class IIa, level of evidence B) [36]. However, there are no ran-
domised controlled studies on effects of combination therapy in HF secondary to 
MR. Recently, in a small observational study Meel et al. showed that combination 
anti-remodelling therapy may be beneficial for HF secondary to chronic rheumatic 
MR with no HF related admissions or deaths, and no deterioration in echocardio-
graphic parameters of ventricular size and function [37].
5. Conclusion
Most of above-mentioned trials were small studies involving vasodilators such 
as ACEIs and beta-blockers in degenerative MR and have been inconclusive. There 
is limited data pertaining to role of medical therapy in rheumatic MR. In general, 
LV dysfunction secondary to primary MR tends to respond poorly compared to LV 
dysfunction complicated by secondary MR. Currently there is no role of medical 
therapy in asymptomatic patients with chronic MR and preserved LV systolic 
function. Larger studies are needed to confirm benefit of medical therapy in 
chronic MR.
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